Skip to main content
Normal View

Dáil Éireann debate -
Wednesday, 17 Oct 2001

Vol. 542 No. 3

Adjournment Debate. - Medical Use of Cannabis.

Mr. Coveney

I am raising this issue for two reasons. First, I want to separate clearly the use of cannabis or hemp plant for medicinal and recreational purposes. This line is constantly being blurred both by those arguing for the general legalisation of cannabis and those who want its prohibition to continue. It is about time we stated the difference between the potential benefits of agents within the cannabis or hemp plant for medicinal purposes and its use, primarily by smoking, for recreational purposes.

Second, I want to assure parents and others that the potential of introducing cannabis or agents within the cannabis plant for medicinal purposes should not frighten people. If it can be shown that there are clear medical benefits from these agents, we should look carefully at the possibility of changing the law to legalise them. A serious debate on recreational drug use is needed, but first we need to put to bed the issue of cannabis for medicinal purposes which should not be allowed to distract or influence that debate. It is an entirely separate issue.

What is meant by medicinal cannabis? It is likely that cannabis will be legalised for medicinal purposes in the UK within two years. Clinical trials on patients with multiple sclerosis, cancer and arthritis have proved encouraging. Tests on 70 British patients show that an extract of the plant sprayed under the tongue or taken in tablet form can significantly reduce pain, muscle spasms and bladder problems. As the doses used in the trials are relatively low, patients do not experience the so-called "high" which many recreational users seek. Large scale trials involving up to 2,000 patients are under way in the UK and should be completed by 2003.

Cannabis contains active ingredients called cannabinoids which alleviate pain, reduce tremors and prevent incontinence. The drug can be sprayed under the tongue so it is absorbed into the bloodstream rather than being swallowed, inhaled or smoked. The applicator allows patients to regulate their dose depending on their level of illness. It is similar to an inhaler used in the treatment of asthma. The UK Government confirmed to the House of Lords science and technology select committee that it would be willing to amend the Misuse of Drugs Act, 1971, to allow the prescription of cannabis-based medicines if trial results continue to be positive.

Many of the health concerns regarding can nabis focus on the toxic effects of cannabis smoke. However, these arguments do not apply as we are not talking about patients smoking cannabis, but taking it in tablet or spray form. Parents or those who view the legalisation of cannabis for medical use as the first step towards the legalisation of the drug generally, are sorely mistaken. According to this rationale, morphine, for example, which is the main agent in heroin, would not be available on prescription as a painkiller. We all recognise the benefits of morphine as a painkiller in extreme circumstances.

The negative aspects of smoking cannabis as a recreational drug are well known and more than convince me that we should not legalise the drug for recreational use under any circumstances. As regards the short-term effects such as memory loss or distorted perception, or the long-term and more important carcinogenic effects, the recreational smoking of cannabis is unacceptable and the drug should not be legalised. However, the medicinal benefits should be examined in detail. We should separate the issues, examine the potential positive effects and support and take an interest in the research under way in the UK. Canada has already legalised the use of cannabis for medicinal purposes and I look forward to the Minister of State's response.

I thank the Deputy for raising this matter and, on behalf of the Minister, giving me the opportunity to clarify the position regarding cannabis. As the Deputy will know a new national drugs strategy, 2001 to 2008, entitled Building on Experience was launched by the Taoiseach in May this year. The overall objective of the strategy is to significantly reduce the harm caused to individuals and society by the misuse of drugs through a concerted focus on supply reduction, prevention, treatment and research. The document sets out 100 actions regarding tackling the drugs problem and has also identified key performance indicators which will help measure the effectiveness of these actions. In the consultation process leading up to the publication of the document there was little or no debate about the medicinal use of cannabis. The Deputy has clearly outlined his stance on this debate.

Cannabis is a Schedule 1 controlled drug under the Misuse of Drugs Acts, 1977 and 1984. It is also one of the controlled drugs which has been designated for the purposes of section 13 of the Misuse of Drugs Act, 1977. The nature of the controls provided in this manner are those which, according to the current UN conventions on narcotic drugs and psychotropic substances, must be applied to substances such as cannabis and cannabis resin, for which there is no current recognised medical or scientific use. Under these laws the manufacture, possession, supply, and pre scription of the drug are prohibited, except under licence from the Minister for Health and Children.

By virtue of the designation under section 13 of the Act, licences may be granted for the purpose of research or forensic analysis, or in respect of the use of the drug as an essential intermediate or starting material in an industrial manufacturing process. Furthermore, the Minister for Health and Children must be satisfied in regard to the scientific or medical justification offered in support of the grant of any licence involving any of the designated controlled drugs such as cannabis. Licences may also be granted in the case of certain low tetrahydrocannabinol plant varieties of cannabis for the growing of hemp. I am aware that claims are being made in respect of cannabis concerning the possible benefits for patients suffering from certain conditions such as multiple sclerosis and glaucoma. However, these medical claims are not currently supported by the results of recognised medical research.

In order to conduct research into the medicinal use of cannabis in this country, a permission from the Irish Medicines Board would be required. If the Irish Medicines Board was to grant such a permission under the Control of Clinical Trials Act, 1987, to facilitate conducting a trial in respect of a medicinal product containing cannabis, the Minister for Health and Children would be prepared to give serious consideration to the granting of the necessary licence(s) under the Misuse of Drugs Acts.

The Dáil adjourned at 9.30 p.m. until 10.30 a.m. on Thursday, 18 October 2001.

Top
Share